Small Pharma Inc.
DMTTF · OTC
2/28/2023 | 2/28/2022 | 2/28/2021 | 2/29/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.86 | -0.02 | 0.00 | 0.00 |
| FCF Yield | -74.99% | -17.56% | -3.04% | 0.00% |
| EV / EBITDA | -0.48 | -2.36 | -15.01 | 0.00 |
| Quality | ||||
| ROIC | -128.32% | -42.14% | -183.88% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.73 | 0.60 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 426,513.02% | -100.00% |
| Free Cash Flow Growth | -36.88% | -276.09% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.73 | 1.85 | -0.32 | 0.00 |
| Interest Coverage | 0.00 | -41.39 | -11.59 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 2,237.17 | 0.00 |